Novartis has received US FDA approval for its immunosuppressive drug Zortress to prevent organ rejection in adult kidney transplant recipients.
The new drug is approved to prevent organ rejection, while reducing the side effects of treatment regimens containing cyclosporine, and to inhibit the proliferation of cells that play a key role in transplant rejection.
Zortress (everolimus) oral tablets will be given in combination with reduced doses of the calcineurin inhibitor cyclosporine, basiliximab and corticosteroids.
In a Phase III registration study, Zortress prevented acute organ rejection and preserved kidney function.
The drug has been available in 70 countries outside the US under the brand name Certican.
Novartis said that an estimated 83,000 patients are awaiting kidney transplantation in the US as of March 2010.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData